Analysts Anticipate Cronos Group Inc (NASDAQ:CRON) Will Announce Quarterly Sales of $8.45 Million

Wall Street analysts predict that Cronos Group Inc (NASDAQ:CRON) will report $8.45 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Cronos Group’s earnings, with the highest sales estimate coming in at $10.80 million and the lowest estimate coming in at $6.00 million. Cronos Group reported sales of $7.65 million in the same quarter last year, which indicates a positive year-over-year growth rate of 10.5%. The business is expected to report its next quarterly earnings report on Thursday, August 13th.

According to Zacks, analysts expect that Cronos Group will report full-year sales of $43.92 million for the current fiscal year, with estimates ranging from $34.80 million to $50.60 million. For the next year, analysts forecast that the company will report sales of $109.40 million, with estimates ranging from $83.30 million to $174.00 million. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for Cronos Group.

Cronos Group (NASDAQ:CRON) last issued its earnings results on Friday, May 8th. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.27. Cronos Group had a net margin of 2,705.97% and a return on equity of 0.72%. The firm had revenue of $8.40 million for the quarter, compared to analyst estimates of $13.05 million. During the same quarter last year, the business posted $0.48 earnings per share. The company’s quarterly revenue was up 29.2% on a year-over-year basis.

A number of equities analysts have recently commented on CRON shares. Stifel Nicolaus cut their price target on shares of Cronos Group from $8.00 to $7.50 and set a “hold” rating on the stock in a report on Monday, May 11th. Zacks Investment Research upgraded shares of Cronos Group from a “sell” rating to a “hold” rating and set a $5.50 target price on the stock in a report on Monday, May 11th. Raymond James set a $6.50 target price on shares of Cronos Group and gave the company a “market perform” rating in a report on Friday. Piper Sandler lowered shares of Cronos Group from an “overweight” rating to a “neutral” rating in a report on Sunday, April 19th. Finally, Canaccord Genuity restated a “sell” rating and issued a $6.50 target price on shares of Cronos Group in a report on Monday, May 11th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $9.05.

Shares of NASDAQ:CRON opened at $6.70 on Friday. The firm has a market cap of $1.93 billion, a PE ratio of 7.28 and a beta of 1.91. The firm’s fifty day moving average is $5.73 and its 200-day moving average is $6.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.75 and a current ratio of 6.97. Cronos Group has a 52 week low of $4.00 and a 52 week high of $17.86.

A number of institutional investors and hedge funds have recently bought and sold shares of CRON. APG Asset Management N.V. bought a new stake in shares of Cronos Group during the first quarter worth about $448,000. Valinor Management L.P. increased its position in shares of Cronos Group by 62.1% during the first quarter. Valinor Management L.P. now owns 469,322 shares of the company’s stock worth $2,661,000 after acquiring an additional 179,722 shares in the last quarter. Voloridge Investment Management LLC increased its position in shares of Cronos Group by 74.7% during the first quarter. Voloridge Investment Management LLC now owns 169,571 shares of the company’s stock worth $961,000 after acquiring an additional 72,517 shares in the last quarter. Advisor Group Holdings Inc. bought a new stake in shares of Cronos Group during the first quarter worth about $1,405,000. Finally, CIBC World Markets Inc. increased its position in shares of Cronos Group by 40.2% during the first quarter. CIBC World Markets Inc. now owns 28,837 shares of the company’s stock worth $164,000 after acquiring an additional 8,275 shares in the last quarter. 14.39% of the stock is owned by hedge funds and other institutional investors.

About Cronos Group

Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations “MMPR”. The firm typically invests in companies based in Canada.

Featured Article: Trade War

Get a free copy of the Zacks research report on Cronos Group (CRON)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cronos Group (NASDAQ:CRON)

Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply